Hanan

I am very optimistic and ambitious girl. I see possibilities in every thing. I like to share and I love to help others in the best way I can.

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#EHA2026 EHA Guidelines on management of chronic lymphocytic
leukemia and Richter transformation @Hemasphere_EHA

https://t.co/S3IztQMdu9

#lymsm #leusm #hematology

[GvHD Hub @gvhd_hub]

CONGRESS | #cGvHD2026 | ORAL PRESENTATION

Steven Pavletic provides an update on belumosudil 5 years after its approval in #cGvHD. He reviews the ROCKstar trial data that supported regulatory approval, along with findings from the ROCKstar companion study demonstrating tissue-level responses to belumosudil, including reduced collagen, T cells, and IL-17–producing cells in the oral buccal mucosa. He also discusses combination strategies involving belumosudil and outlines future directions such as moving the agent into earlier lines of therapy.

Follow our live feed for more updates: https://t.co/Z8MqTc6beZ

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#GvHD #GvHDsm #MedNews #MedEd @StevenPavletic

[Hanan @hanoon8Amoon]

@TShykh68737 6
كل عام وأنتم بخير

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Nature Portfolio @NaturePortfolio]

A Review in @NatRevClinOncol discusses the promises and limitations of liquid biopsy-based tests for multi-cancer early detection. https://t.co/ENgYJvjGkJ 🔒

[التواصل الحكومي @CGCSaudi]

ليست مجرد خلايا تُزرع، بل قصة تُكتب؛ الدكتور محمود الجرف غدًا في المنافس العالمي.

[ESMO - Eur. Oncology @myESMO]

📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines

🔗https://t.co/Xut0qRrS8h

[JAMA @JAMA_current]

Staphylococcus aureus bacteremia has a case fatality rate of 15% to 30% and causes 300 000 deaths per year worldwide.

This Review discusses management of S aureus bacteremia.

https://t.co/BYBHl4uBeI

[Oren Gottfried, MD @OGdukeneurosurg]

Chemotherapy

[GvHD Hub @gvhd_hub]

In case you missed it:

Is sirolimus an alternative option to tacrolimus for GvHD prophylaxis following haploidentical allo-HCT?

🔎Find out more in our visual abstract: https://t.co/tutuRdogKN

#GvHDsm

[برنامج خادم الحرمين الشريفين للابتعاث @SA_Scholarships]

فترات بدء الترشيح
لبرنامج خادم الحرمين
الشريفين للابتعاث
للعام الأكاديمي
2025-2024

#قدراتك_مستقبلنا

[NursingCenter @NursingCenter]

Featured Journal! Explore the current issue of Clinical Nurse Specialist: https://t.co/m6D7X0Axzh

#Nurses #ClinicalNurseSpecialist

[IVAL Water - مياه ايفال @IvalWater]

لعملاء #مياه_ايفال خلك قريب ..
يمكن تكون أنت الفائز! 🤩

سحب يومي على جهاز ايفون 15 برو 📱
كل اللي عليك تتابع حسابنا وتفعّل التنبيهات
وفالك الفوز في شهر الخير

#مسابقة_ايفال_الرمضانية 🌙

[ICU OnePager @OnePagerICU]

Comparison of methods for determining fluid responsiveness & tolerance
https://t.co/eFQIUcNlsS

[Nico Gagelmann @NicoGagelmann]

🎉Finally published🎉

How I treat: myelofibrosis with transplant

#mpnsm @BloodJournal

Free access👇
https://t.co/iwmQSAgSA4

[Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx @CARTTherapy]

The academic anti-CD19 CAR-T varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory NHL #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy
@ASTCT
@CART_Therapy
https://t.co/3MsFYinQf6

[Blood Journals Portfolio @BloodPortfolio]

How I treat posttransplant lymphoproliferative disorder
https://t.co/z6FLc2vOUf #howitreat #lymphoidneoplasia #transplantation

[JAMA @JAMA_current]

Today an FDA advisory committee considers a gene editing treatment for sickle cell disease.

This short explains the principles of DNA editing with #CRISPR-Cas9 and the rationale for its use.

Watch the video in full: https://t.co/gUNwzj4dkY

[ASH @ASH_hematology]

Study: Individuals with severe #sicklecell disease are highly interested in new, potentially curative gene therapy treatments and willing to accept associated risks for a chance at a cure.

Read more: https://t.co/LDA2LuEDj3 @BloodAdvances #genetherapy @CayenneWellness @DukeU